Scientific Publications by FDA Staff
Immunotherapy 2012 Apr;4(4):443-51
IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H, Husain SR, Puri RK
Many immunotherapy approaches including therapeutic cancer vaccines targeting specific tumor-associated antigens are at various stages of development. Although the significance of overexpression of (IL-13Ralpha2) in cancer is being actively investigated, we have reported that IL-13Ralpha2 is a novel tumor-associated antigen. The IL-13Ralpha2-directed cancer vaccine is one of the most promising approaches to tumor immunotherapy, because of the selective expression of IL-13Ralpha2 in various solid tumor types but not in normal tissues. In this article, we will summarize its present status and potential strategies to improve IL-13Ralpha2-directed cancer vaccines for an optimal therapy of cancer.
|Category: Journal Article, Review|
|PubMed ID: #22512637||DOI: 10.2217/IMT.12.28|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2012-04-20||Entry Last Modified: 2012-08-29|